Artificial Intelligence (AI) in Drug Discovery Market - Global Outlook & Forecast 2025-2030

List of Tables

The global AI in drug discovery market is expected to grow at a CAGR of 30.58% from 2024 to 2030.

MARKET TRENDS & DRIVERS

Integration of AI with Big Data and Omics Technologies

The integration of AI with big data and omics technologies is reshaping the global drug discovery market. By enabling a deeper understanding of biological systems, improving efficiency, and driving personalized medicine, this trend is creating unprecedented opportunities for innovation and growth. Overcoming existing challenges will further cement its role as a transformative force in the healthcare and pharmaceutical industries. The future of drug discovery is undeniably data-driven, with AI at its core.

Increasing Use of Generative AI Models

The increasing use of generative AI models in the global AI in drug discovery market marks a paradigm shift in how pharmaceutical research and development are conducted. By enabling faster, cheaper, and more precise drug development, these models are creating new opportunities across the healthcare ecosystem. As technology continues to evolve, generative AI is set to redefine the boundaries of what is possible in drug discovery, offering hope for faster cures, more personalized treatments, and a healthier future.

Emergence of AI-Driven Drug Repurposing

The emergence of AI-driven drug repurposing is a game-changer in the global drug discovery market, transforming traditional approaches and creating exciting new opportunities. By reducing costs, accelerating timelines, and addressing unmet medical needs, AI-driven drug repurposing is shaping the future of pharmaceutical innovation. As AI technologies continue to evolve, their integration into drug repurposing will undoubtedly unlock even greater potential, benefiting both the industry and global healthcare systems.

Growing Partnerships between Pharmaceutical Companies and AI-focused Expertise

The growing partnerships between pharmaceutical companies and AI-focused expertise are transforming the global drug discovery landscape. By leveraging AI's capabilities to overcome traditional challenges, these collaborations are creating new opportunities for faster, more cost-effective, and innovative drug development. As the pharmaceutical industry continues to embrace AI, the synergies between these two domains will not only drive market growth but also pave the way for groundbreaking advancements in medicine, ultimately benefiting patients worldwide.

Advancements in Computing Power and Cloud Technologies

The convergence of computing power and cloud technologies has become a driving force in the global AI in drug discovery market. These advancements are empowering pharmaceutical companies and research institutions to revolutionize drug development processes, making them faster, more efficient, and more accessible. As technology continues to evolve, the synergy between AI, computing, and cloud platforms will play an increasingly central role in addressing unmet medical needs and advancing healthcare innovation worldwide.

Rising R&D Costs in Drug Discovery

The rising costs of R&D in drug discovery are pushing the pharmaceutical industry to embrace innovative solutions, and AI is emerging as a powerful enabler. By reducing expenses, improving success rates, and accelerating development timelines, AI is addressing critical pain points in the industry. As the global AI in drug discovery market continues to expand, it holds the potential to not only alleviate financial pressures but also revolutionize healthcare by delivering innovative treatments more efficiently and effectively.

Growing Volume of Biological and Clinical Data

The growing volume of biological and clinical data is a driving force in the global AI in drug discovery market. By enabling the analysis of vast and complex datasets, AI is revolutionizing target identification, drug screening, and personalized medicine. Although challenges remain, the synergy between AI and data promises to unlock new frontiers in drug discovery, improving global health outcomes and addressing unmet medical needs. As this trend continues, AI will remain at the forefront of innovation, reshaping the pharmaceutical landscape.

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases has created a pressing need for innovative and efficient drug discovery methods. AI has emerged as a transformative tool, enabling the rapid identification of potential drug candidates, optimizing clinical trials, and accelerating the development of personalized therapies. As chronic diseases continue to rise globally, the adoption of AI in drug discovery is poised to grow, driving advancements in healthcare and improving patient outcomes. With continued investments and collaborations, the global AI in drug discovery market is set to play a pivotal role in addressing one of the most significant healthcare challenges of our time.

SEGMENTATION INSIGHTS

INSIGHTS BY APPLICATION

The global AI in drug discovery market by application is segmented into drug repurposing, drug screening, drug design & optimization, and others. The drug repurposing segment held the largest market share. Drug repurposing refers to the identification of new therapeutic uses for existing drugs. AI significantly enhances this process by analyzing massive datasets, including genomics, clinical trials, and real-world evidence, to identify potential drug-disease pairings. Drug screening involves the evaluation of thousands of compounds to identify potential candidates for further development. AI-powered screening significantly accelerates this traditionally time-intensive process.

AI is revolutionizing drug design and optimization by generating novel molecular structures and refining existing compounds for improved efficacy, safety, and pharmacokinetics. Beyond the core applications, AI is being deployed in various other aspects of drug discovery, such as clinical trial optimization, biomarker discovery, and toxicity prediction. Furthermore, the global AI in drug discovery market is expected to witness sustained growth across all applications. Advances in AI technologies, increasing adoption of cloud computing, and deeper integration of AI into the pharmaceutical pipeline will drive innovation and efficiency. As more companies and research institutions embrace AI-driven approaches, the potential to bring safer, more effective therapies to market faster and at a lower cost is becoming a reality.

Segmentation by Application

Drug Repurposing
Drug Screening
Drug Design & Optimization
Others

INSIGHTS BY THERAPEUTIC AREA

The global AI in drug discovery market spans various therapeutic areas, leveraging AI to enhance research and development across diverse medical conditions. AI's ability to analyze vast datasets, identify potential drug candidates, and streamline development pipelines has significantly impacted therapeutic segments, addressing critical healthcare challenges. In 2024, the oncological disorders therapeutic area segment held the largest global AI in drug discovery market share. One of the primary applications of AI in oncological drug discovery is in identifying novel therapeutic targets. AI-powered algorithms analyze genomic and transcriptomic data to pinpoint genes and proteins involved in tumor progression. Furthermore, the integration of multi-omics data improved predictive analytics, and collaboration between stakeholders will further enhance therapeutic innovation, shaping the future of drug discovery worldwide.

Segmentation by Therapeutic Area

Oncological Disorders
CNS Disorders
Infectious Diseases
Immunological Disorders
Cardiovascular Disorders
Gastrointestinal Disorders
Others

INSIGHTS BY DRUG TYPE

The small molecule drug type holds the most significant share of the global AI in drug discovery market, largely due to their established role in treating a broad range of diseases. These drugs are chemically synthesized, relatively inexpensive to manufacture, and have a proven track record in pharmaceutical applications. AI tools like generative models and machine learning algorithms are extensively used to design and optimize small molecule drugs by predicting their interactions with biological targets, toxicity profiles, and pharmacokinetics. Biologics, including monoclonal antibodies, vaccines, and gene therapies, are gaining traction due to their specificity and efficacy in targeting complex diseases. AI technologies like neural networks are employed to analyze biological data, identify novel protein structures, and optimize biologics' development.

Segmentation by Drug Type

Small Molecule
Biologics

INSIGHTS BY TECHNOLOGY

The global AI in drug discovery market by technology is segmented into machine learning (ML), deep learning, natural language processing (NLP), and others. The machine learning (ML) segment holds the largest market share in 2024. ML is the most widely used technology in AI-driven drug discovery. It enables the analysis of large datasets, identifies hidden patterns, and accelerates the drug development process. Its ability to process vast amounts of structured and unstructured data makes it indispensable for drug discovery. Also, machine learning also plays a critical role in optimizing clinical trial design and execution. By analyzing patient data, ML algorithms can identify suitable patient cohorts for trials, predict patient responses, and reduce dropout rates.

Deep learning uses artificial neural networks to analyze highly complex data, such as genomics, proteomics, and imaging. The deep learning segment is also projected to witness significant growth during the forecast period. Deep learning is particularly useful in structure-based drug design, biomarker discovery, and disease pathway analysis. Moreover, deep learning facilitates lead optimization by predicting the pharmacokinetics and toxicity profiles of drug candidates. Predictive models trained on historical data help refine chemical structures to enhance efficacy, safety, and bioavailability. This minimizes the chances of late-stage failures, a common challenge in traditional drug development.

Segmentation by Technology

Machine Learning (ML)
Deep Learning
Natural Language Processing (NLP)
Others

INSIGHTS BY END-USER

The global AI in drug discovery market by end-user is segmented into pharma & biotech companies, CROs & CDMOs, and others. The increasing adoption of AI across all end-user segments reflects the growing recognition of its transformative potential in drug discovery. Pharma & biotech companies will continue to lead the market, leveraging AI to address R&D inefficiencies and enhance drug pipelines. As AI technologies continue to advance, the role of pharma and biotech companies as end-users will be instrumental in shaping the future of medicine, addressing unmet medical needs, and improving global health outcomes. Meanwhile, CROs & CDMOs will see steady growth due to the rise in outsourcing trends, and academic institutions will remain pivotal in driving fundamental innovations. Government organizations will focus on fostering a regulatory and infrastructural environment conducive to AI adoption, ensuring the market's sustained expansion.

Segmentation by End-user

Pharma & Biotech Companies
Contract Research Organizations (CROs) & Contract Development and Manufacturing Organizations (CDMOs)
Others

GEOGRAPHICAL ANALYSIS

The global AI in drug discovery market exhibits significant regional diversity, with each geography offering unique opportunities and challenges. North America leads the global AI in drug discovery market accounting for a global share of over 43% in 2024, driven by its advanced technological ecosystem, robust pharmaceutical and biotechnology sectors, and substantial investments in research and development. The region is home to key players, innovative startups, and extensive academic and research collaborations that position it at the forefront of AI adoption in drug discovery. Also, the U.S. is home to leading AI companies, research institutions, and pharmaceutical giants, fostering a strong ecosystem for AI integration in drug discovery. Companies such as IBM Watson, NVIDIA, and Google DeepMind are collaborating with pharmaceutical firms to accelerate AI-driven drug development.

Europe holds a significant share in the AI in drug discovery market, driven by its strong research networks, public-private partnerships, and supportive regulatory frameworks. European countries focus on secure data sharing and ethical AI deployment, supported by frameworks like GDPR. This ensures the responsible use of patient data in drug development. Also, strong Biotech Sector: Countries like Germany, France, and the UK are at the forefront of AI-driven drug discovery, with a thriving biotech industry and state-of-the-art research facilities.

Furthermore, the APAC region is witnessing exponential growth in the AI in drug discovery market, fueled by increasing healthcare investments, a growing pharmaceutical sector, and government support. Countries like China, Japan, and India have launched national AI strategies to boost innovation in drug discovery. For instance, China's "Next Generation Artificial Intelligence Development Plan" prioritizes AI integration across healthcare. Furthermore, the Middle East, Africa, and Latin America represent nascent but promising markets driven by government support and increasing investments in healthcare innovation. These regional dynamics collectively contribute to the global market's expansion, underscoring the transformative potential of AI in revolutionizing drug discovery.

Segmentation by Geography

North America
- The U.S.
- Canada
Europe
- Germany
- The U.K.
- Switzerland
- France
- Italy
- Spain
- Netherlands
APAC
- China
- Japan
- India
- South Korea
- Australia
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
Middle East & Africa
- Turkey
- South Africa
- Saudi Arabia
- UAE

VENDOR LANDSCAPE

The global AI in drug discovery market has witnessed significant growth in recent years as pharmaceutical companies increasingly adopt AI to accelerate and optimize drug discovery processes. AI-powered technologies, including machine learning (ML), deep learning, and natural language processing (NLP), are enabling researchers to navigate the complexity of biological systems, analyze vast biomedical datasets, and identify promising drug candidates faster and at reduced costs. The competitive landscape of the global AI in drug discovery market is marked by the presence of established pharmaceutical companies, AI technology providers, and emerging startups, all vying to gain a foothold in this rapidly evolving domain. Moreover, companies like IBM Watson Health, Google DeepMind, and NVIDIA, are significant players in the AI in drug discovery market offering advanced AI platforms tailored for drug discovery. For instance, IBM Watson leverages natural language processing and machine learning to mine scientific literature and identify drug targets. Google DeepMind, through its AlphaFold system, has revolutionized protein structure prediction, enabling faster and more precise identification of potential drug candidates.

Leading pharmaceutical firms such as Pfizer, Novartis, Roche, and AstraZeneca have incorporated AI technologies into their research pipelines. These companies are increasingly collaborating with AI startups to drive innovation. For example, AstraZeneca partnered with BenevolentAI to leverage machine learning algorithms for target identification and drug repurposing, showcasing the synergistic potential of AI in pharmaceutical R&D. Furthermore, startups and specialized AI companies, such as BenevolentAI, Insilico Medicine, Atomwise, Exscientia, and Recursion Pharmaceuticals, are at the forefront in the AI in drug discovery market. These companies have developed AI algorithms capable of analyzing complex biological data, predicting molecular interactions, and accelerating preclinical drug discovery stages.

Key Company Profiles

Atomwise
Amazon Web Services (AWS)
BenevolentAI
Google
IBM
Insilico Medicine
Microsoft
NVIDIA
Recursion Pharmaceuticals

Other Prominent Vendors

AbCellera
Aitia
BenchSci
BioSymetrics
BPGbio
Centella
Envisagenics
EVAXION Biotech A/S
Iktos
Illumina
insitro
Merck KGaA
Model Medicine
NuMedii
Owkin
Predictive Oncology
Relay Therapeutics
Standigm
Valo Health
Verge Genomics
XtalPi

KEY QUESTIONS ANSWERED:

1. How big is the global AI in drug discovery market?

2. What is the growth rate of the global AI in drug discovery market?

3. Which region dominates the global AI in drug discovery market share?

4. What are the significant trends in the AI in drug discovery industry?

5. Who are the key players in the global AI in drug discovery market?

Product Code: ARZ250108

1. SCOPE & COVERAGE

1.1. MARKET DEFINITION
- 1.1.1. INCLUSIONS
- 1.1.2. EXCLUSIONS
- 1.1.3. MARKET ESTIMATION CAVEATS
1.2. SEGMENTS COVERED & DEFINITION
- 1.2.1. MARKET SEGMENTATION BY APPLICATION
- 1.2.2. MARKET SEGMENTATION BY THERAPEUTIC AREA
- 1.2.3. MARKET SEGMENTATION BY DRUG TYPE
- 1.2.4. MARKET SEGMENTATION BY TECHNOLOGY
- 1.2.5. MARKET SEGMENTATION BY END-USER
- 1.2.6. REGIONS & COUNTRIES COVERED
1.3. MARKET DERIVATION
- 1.3.1. HISTORIC, BASE, & FORECAST YEARS

2. PREMIUM INSIGHTS

2.1. OPPORTUNITY POCKETS
2.2. OVERVIEW

3. MARKET AT A GLANCE

4. INTRODUCTION

4.1. OVERVIEW

5. MARKET OPPORTUNITIES & TRENDS

5.1. INTEGRATION OF AI WITH BIG DATA AND OMICS TECHNOLOGIES
5.2. INCREASE IN USE OF GENERATIVE AI MODELS
5.3. EMERGENCE OF AI-DRIVEN DRUG REPURPOSING
5.4. GROWTH IN PARTNERSHIPS BETWEEN PHARMACEUTICAL COMPANIES AND AI-FOCUSED EXPERTISE

6. MARKET GROWTH ENABLERS

6.1. ADVANCES IN COMPUTING POWER AND CLOUD TECHNOLOGIES
6.2. RISE IN R&D COSTS IN DRUG DISCOVERY
6.3. GROWTH IN VOLUME OF BIOLOGICAL AND CLINICAL DATA
6.4. INCREASE IN PREVALENCE OF CHRONIC DISEASES

7. MARKET RESTRAINTS

7.1. HIGH INITIAL COSTS OF AI IMPLEMENTATION
7.2. DATA PRIVACY & SECURITY CONCERNS
7.3. REGULATORY & ETHICAL CHALLENGES

8. MARKET LANDSCAPE

8.1. MARKET OVERVIEW
8.2. MARKET SIZE & FORECAST
8.3. FIVE FORCES ANALYSIS
- 8.3.1. THREAT OF NEW ENTRANTS
- 8.3.2. BARGAINING POWER OF SUPPLIERS
- 8.3.3. BARGAINING POWER OF BUYERS
- 8.3.4. THREAT OF SUBSTITUTES
- 8.3.5. COMPETITIVE RIVALRY

9. APPLICATION

9.1. MARKET SNAPSHOT & GROWTH ENGINE
9.2. MARKET OVERVIEW
9.3. DRUG REPURPOSING
- 9.3.1. MARKET OVERVIEW
- 9.3.2. MARKET SIZE & FORECAST
- 9.3.3. MARKET BY GEOGRAPHY
9.4. DRUG SCREENING
- 9.4.1. MARKET OVERVIEW
- 9.4.2. MARKET SIZE & FORECAST
- 9.4.3. MARKET BY GEOGRAPHY
9.5. DRUG DESIGN & OPTIMIZATION
- 9.5.1. MARKET OVERVIEW
- 9.5.2. MARKET SIZE & FORECAST
- 9.5.3. MARKET BY GEOGRAPHY
9.6. OTHERS
- 9.6.1. MARKET OVERVIEW
- 9.6.2. MARKET SIZE & FORECAST
- 9.6.3. MARKET BY GEOGRAPHY

10. THERAPEUTIC AREA

10.1. MARKET SNAPSHOT & GROWTH ENGINE
10.2. MARKET OVERVIEW
10.3. ONCOLOGICAL DISORDERS
- 10.3.1. MARKET OVERVIEW
- 10.3.2. MARKET SIZE & FORECAST
- 10.3.3. MARKET BY GEOGRAPHY
10.4. CENTRAL NERVOUS SYSTEM (CNS) DISORDERS
- 10.4.1. MARKET OVERVIEW
- 10.4.2. MARKET SIZE & FORECAST
- 10.4.3. MARKET BY GEOGRAPHY
10.5. INFECTIOUS DISEASES
- 10.5.1. MARKET OVERVIEW
- 10.5.2. MARKET SIZE & FORECAST
- 10.5.3. MARKET BY GEOGRAPHY
10.6. IMMUNOLOGICAL DISORDERS
- 10.6.1. MARKET OVERVIEW
- 10.6.2. MARKET SIZE & FORECAST
- 10.6.3. MARKET BY GEOGRAPHY
10.7. CARDIOVASCULAR DISORDERS (CVDS)
- 10.7.1. MARKET OVERVIEW
- 10.7.2. MARKET SIZE & FORECAST
- 10.7.3. MARKET BY GEOGRAPHY
10.8. GASTROINTESTINAL DISORDERS
- 10.8.1. MARKET OVERVIEW
- 10.8.2. MARKET SIZE & FORECAST
- 10.8.3. MARKET BY GEOGRAPHY
10.9. OTHERS
- 10.9.1. MARKET OVERVIEW
- 10.9.2. MARKET SIZE & FORECAST
- 10.9.3. MARKET BY GEOGRAPHY

11. DRUG TYPE

11.1. MARKET SNAPSHOT & GROWTH ENGINE
11.2. MARKET OVERVIEW
11.3. SMALL MOLECULE
- 11.3.1. MARKET OVERVIEW
- 11.3.2. MARKET SIZE & FORECAST
- 11.3.3. MARKET BY GEOGRAPHY
11.4. BIOLOGICS
- 11.4.1. MARKET OVERVIEW
- 11.4.2. MARKET SIZE & FORECAST
- 11.4.3. MARKET BY GEOGRAPHY

12. TECHNOLOGY

12.1. MARKET SNAPSHOT & GROWTH ENGINE
12.2. MARKET OVERVIEW
12.3. MACHINE LEARNING (ML)
- 12.3.1. MARKET OVERVIEW
- 12.3.2. MARKET SIZE & FORECAST
- 12.3.3. MARKET BY GEOGRAPHY
12.4. DEEP LEARNING
- 12.4.1. MARKET OVERVIEW
- 12.4.2. MARKET SIZE & FORECAST
- 12.4.3. MARKET BY GEOGRAPHY
12.5. NATURAL LANGUAGE PROCESSING (NLP)
- 12.5.1. MARKET OVERVIEW
- 12.5.2. MARKET SIZE & FORECAST
- 12.5.3. MARKET BY GEOGRAPHY
12.6. OTHERS
- 12.6.1. MARKET OVERVIEW
- 12.6.2. MARKET SIZE & FORECAST
- 12.6.3. MARKET BY GEOGRAPHY

13. END-USER

13.1. MARKET SNAPSHOT & GROWTH ENGINE
13.2. MARKET OVERVIEW
13.3. PHARMA & BIOTECH COMPANIES
- 13.3.1. MARKET OVERVIEW
- 13.3.2. MARKET SIZE & FORECAST
- 13.3.3. MARKET BY GEOGRAPHY
13.4. CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS (CDMOS)
- 13.4.1. MARKET OVERVIEW
- 13.4.2. MARKET SIZE & FORECAST
- 13.4.3. MARKET BY GEOGRAPHY
13.5. OTHERS
- 13.5.1. MARKET OVERVIEW
- 13.5.2. MARKET SIZE & FORECAST
- 13.5.3. MARKET BY GEOGRAPHY

14. GEOGRAPHY

14.1. MARKET SNAPSHOT & GROWTH ENGINE
14.2. GEOGRAPHIC OVERVIEW

15. NORTH AMERICA

15.1. MARKET OVERVIEW
15.2. MARKET SIZE & FORECAST
- 15.2.1. APPLICATION
- 15.2.2. THERAPEUTIC AREA
- 15.2.3. DRUG TYPE
- 15.2.4. TECHNOLOGY
- 15.2.5. END-USER
15.3. KEY COUNTRIES
- 15.3.1. US: MARKET SIZE & FORECAST
- 15.3.2. CANADA: MARKET SIZE & FORECAST

16. EUROPE

16.1. MARKET OVERVIEW
16.2. MARKET SIZE & FORECAST
- 16.2.1. APPLICATION
- 16.2.2. THERAPEUTIC AREA
- 16.2.3. DRUG TYPE
- 16.2.4. TECHNOLOGY
- 16.2.5. END-USER
16.3. KEY COUNTRIES
- 16.3.1. GERMANY: MARKET SIZE & FORECAST
- 16.3.2. UK: MARKET SIZE & FORECAST
- 16.3.3. SWITZERLAND: MARKET SIZE & FORECAST
- 16.3.4. FRANCE: MARKET SIZE & FORECAST
- 16.3.5. ITALY: MARKET SIZE & FORECAST
- 16.3.6. SPAIN: MARKET SIZE & FORECAST
- 16.3.7. NETHERLANDS: MARKET SIZE & FORECAST

17. APAC

17.1. MARKET OVERVIEW
17.2. MARKET SIZE & FORECAST
- 17.2.1. APPLICATION
- 17.2.2. THERAPEUTIC AREA
- 17.2.3. DRUG TYPE
- 17.2.4. TECHNOLOGY
- 17.2.5. END-USER
17.3. KEY COUNTRIES
- 17.3.1. CHINA: MARKET SIZE & FORECAST
- 17.3.2. JAPAN: MARKET SIZE & FORECAST
- 17.3.3. INDIA: MARKET SIZE & FORECAST
- 17.3.4. SOUTH KOREA: MARKET SIZE & FORECAST
- 17.3.5. AUSTRALIA: MARKET SIZE & FORECAST

18. LATIN AMERICA

18.1. MARKET OVERVIEW
18.2. MARKET SIZE & FORECAST
- 18.2.1. APPLICATION
- 18.2.2. THERAPEUTIC AREA
- 18.2.3. DRUG TYPE
- 18.2.4. TECHNOLOGY
- 18.2.5. END-USER
18.3. KEY COUNTRIES
- 18.3.1. BRAZIL: MARKET SIZE & FORECAST
- 18.3.2. MEXICO: MARKET SIZE & FORECAST
- 18.3.3. ARGENTINA: MARKET SIZE & FORECAST
- 18.3.4. COLOMBIA: MARKET SIZE & FORECAST

19. MIDDLE EAST & AFRICA

19.1. MARKET OVERVIEW
19.2. MARKET SIZE & FORECAST
- 19.2.1. APPLICATION
- 19.2.2. THERAPEUTIC AREA
- 19.2.3. DRUG TYPE
- 19.2.4. TECHNOLOGY
- 19.2.5. END-USER
19.3. KEY COUNTRIES
- 19.3.1. TURKEY: MARKET SIZE & FORECAST
- 19.3.2. SOUTH AFRICA: MARKET SIZE & FORECAST
- 19.3.3. SAUDI ARABIA: MARKET SIZE & FORECAST
- 19.3.4. UAE: MARKET SIZE & FORECAST

20. COMPETITIVE LANDSCAPE

20.1. COMPETITION OVERVIEW
20.2. MARKET SHARE ANALYSIS
- 20.2.1. ATOMWISE
- 20.2.2. AMAZON WEB SERVICES (AWS)
- 20.2.3. BENEVOLENTAI
- 20.2.4. GOOGLE
- 20.2.5. IBM
- 20.2.6. INSILICO MEDICINE
- 20.2.7. MICROSOFT
- 20.2.8. NVIDIA
- 20.2.9. RECURSION PHARMACEUTICALS

21. KEY COMPANY PROFILES

21.1. ATOMWISE
- 21.1.1. BUSINESS OVERVIEW
- 21.1.2. PRODUCT OFFERINGS
- 21.1.3. KEY STRATEGIES
- 21.1.4. KEY STRENGTHS
- 21.1.5. KEY OPPORTUNITIES
21.2. AMAZON WEB SERVICES (AWS)
- 21.2.1. BUSINESS OVERVIEW
- 21.2.2. PRODUCT OFFERINGS
- 21.2.3. KEY STRATEGIES
- 21.2.4. KEY STRENGTHS
- 21.2.5. KEY OPPORTUNITIES
21.3. BENEVOLENTAI
- 21.3.1. BUSINESS OVERVIEW
- 21.3.2. PRODUCT OFFERINGS
- 21.3.3. KEY STRATEGIES
- 21.3.4. KEY STRENGTHS
- 21.3.5. KEY OPPORTUNITIES
21.4. GOOGLE
- 21.4.1. BUSINESS OVERVIEW
- 21.4.2. PRODUCT OFFERINGS
- 21.4.3. KEY STRATEGIES
- 21.4.4. KEY STRENGTHS
- 21.4.5. KEY OPPORTUNITIES
21.5. IBM
- 21.5.1. BUSINESS OVERVIEW
- 21.5.2. PRODUCT OFFERINGS
- 21.5.3. KEY STRATEGIES
- 21.5.4. KEY STRENGTHS
- 21.5.5. KEY OPPORTUNITIES
21.6. INSILICO MEDICINE
- 21.6.1. BUSINESS OVERVIEW
- 21.6.2. PRODUCT OFFERINGS
- 21.6.3. KEY STRATEGIES
- 21.6.4. KEY STRENGTHS
- 21.6.5. KEY OPPORTUNITIES
21.7. MICROSOFT
- 21.7.1. BUSINESS OVERVIEW
- 21.7.2. PRODUCT OFFERINGS
- 21.7.3. KEY STRATEGIES
- 21.7.4. KEY STRENGTHS
- 21.7.5. KEY OPPORTUNITIES
21.8. NVIDIA
- 21.8.1. BUSINESS OVERVIEW
- 21.8.2. PRODUCT OFFERINGS
- 21.8.3. KEY STRATEGIES
- 21.8.4. KEY STRENGTHS
- 21.8.5. KEY OPPORTUNITIES
21.9. RECURSION PHARMACEUTICALS
- 21.9.1. BUSINESS OVERVIEW
- 21.9.2. PRODUCT OFFERINGS
- 21.9.3. KEY STRATEGIES
- 21.9.4. KEY STRENGTHS
- 21.9.5. KEY OPPORTUNITIES

22. OTHER PROMINENT VENDORS

22.1. ABCELLERA
- 22.1.1. BUSINESS OVERVIEW
- 22.1.2. PRODUCT OFFERINGS
22.2. AITIA
- 22.2.1. BUSINESS OVERVIEW
- 22.2.2. PRODUCT OFFERINGS
22.3. BENCHSCI
- 22.3.1. BUSINESS OVERVIEW
- 22.3.2. PRODUCT OFFERINGS
22.4. BIOSYMETRICS
- 22.4.1. BUSINESS OVERVIEW
- 22.4.2. PRODUCT OFFERINGS
22.5. BPGBIO
- 22.5.1. BUSINESS OVERVIEW
- 22.5.2. PRODUCT OFFERINGS
22.6. CENTELLA
- 22.6.1. BUSINESS OVERVIEW
- 22.6.2. PRODUCT OFFERINGS
22.7. ENVISAGENICS
- 22.7.1. BUSINESS OVERVIEW
- 22.7.2. PRODUCT OFFERINGS
22.8. EVAXION BIOTECH A/S
- 22.8.1. BUSINESS OVERVIEW
- 22.8.2. PRODUCT OFFERINGS
22.9. IKTOS
- 22.9.1. BUSINESS OVERVIEW
- 22.9.2. PRODUCT OFFERINGS
22.10. ILLUMINA
- 22.10.1. BUSINESS OVERVIEW
- 22.10.2. PRODUCT OFFERINGS
22.11. INSITRO
- 22.11.1. BUSINESS OVERVIEW
- 22.11.2. PRODUCT OFFERINGS
22.12. MERCK KGAA
- 22.12.1. BUSINESS OVERVIEW
- 22.12.2. PRODUCT OFFERINGS
22.13. MODEL MEDICINE
- 22.13.1. BUSINESS OVERVIEW
- 22.13.2. PRODUCT OFFERINGS
22.14. NUMEDII
- 22.14.1. BUSINESS OVERVIEW
- 22.14.2. PRODUCT OFFERINGS
22.15. OWKIN
- 22.15.1. BUSINESS OVERVIEW
- 22.15.2. PRODUCT OFFERINGS
22.16. PREDICTIVE ONCOLOGY
- 22.16.1. BUSINESS OVERVIEW
- 22.16.2. PRODUCT OFFERINGS
22.17. RELAY THERAPEUTICS
- 22.17.1. BUSINESS OVERVIEW
- 22.17.2. PRODUCT OFFERINGS
22.18. STANDIGM
- 22.18.1. BUSINESS OVERVIEW
- 22.18.2. PRODUCT OFFERINGS
22.19. VALO HEALTH
- 22.19.1. BUSINESS OVERVIEW
- 22.19.2. PRODUCT OFFERINGS
22.20. VERGE GENOMICS
- 22.20.1. BUSINESS OVERVIEW
- 22.20.2. PRODUCT OFFERINGS
22.21. XTALPI
- 22.21.1. BUSINESS OVERVIEW
- 22.21.2. PRODUCT OFFERINGS

23. REPORT SUMMARY

23.1. KEY TAKEAWAYS
23.2. STRATEGIC RECOMMENDATIONS

24. QUANTITATIVE SUMMARY

24.1. MARKET BY APPLICATION
- 24.1.1. NORTH AMERICA
- 24.1.2. EUROPE
- 24.1.3. APAC
- 24.1.4. LATIN AMERICA
- 24.1.5. MIDDLE EAST & AFRICA
24.2. MARKET BY THERAPEUTIC AREA
- 24.2.1. NORTH AMERICA
- 24.2.2. EUROPE
- 24.2.3. APAC
- 24.2.4. LATIN AMERICA
- 24.2.5. MIDDLE EAST & AFRICA
24.3. MARKET BY DRUG TYPE
- 24.3.1. NORTH AMERICA
- 24.3.2. EUROPE
- 24.3.3. APAC
- 24.3.4. LATIN AMERICA
- 24.3.5. MIDDLE EAST & AFRICA
24.4. MARKET BY TECHNOLOGY
- 24.4.1. NORTH AMERICA
- 24.4.2. EUROPE
- 24.4.3. APAC
- 24.4.4. LATIN AMERICA
- 24.4.5. MIDDLE EAST & AFRICA
24.5. MARKET BY END-USER
- 24.5.1. NORTH AMERICA
- 24.5.2. EUROPE
- 24.5.3. APAC
- 24.5.4. LATIN AMERICA
- 24.5.5. MIDDLE EAST & AFRICA
24.6. MARKET BY GEOGRAPHY
- 24.6.1. DRUG REPURPOSING
- 24.6.2. DRUG SCREENING
- 24.6.3. DRUG DESIGN & OPTIMIZATION
- 24.6.4. OTHER APPLICATIONS
- 24.6.5. ONCOLOGICAL DISORDERS
- 24.6.6. CNS DISORDERS
- 24.6.7. INFECTIOUS DISEASES
- 24.6.8. IMMUNOLOGICAL DISORDERS
- 24.6.9. CARDIOVASCULAR DISORDERS
- 24.6.10. GASTROINTESTINAL DISORDERS
- 24.6.11. OTHER THERAPEUTIC AREAS
- 24.6.12. SMALL MOLECULE
- 24.6.13. BIOLOGICS
- 24.6.14. MACHINE LEARNING
- 24.6.15. DEEP LEARNING
- 24.6.16. NATURAL LANGUAGE PROCESSING
- 24.6.17. OTHER TECHNOLOGIES
- 24.6.18. PHARMA & BIOTECH COMPANIES
- 24.6.19. CROS & CDMOS
- 24.6.20. OTHER END-USERS

25. APPENDIX

25.1. RESEARCH METHODOLOGY
25.2. RESEARCH PROCESS
25.3. REPORT ASSUMPTIONS & CAVEATS
- 25.3.1. KEY CAVEATS
- 25.3.2. CURRENCY CONVERSION
25.4. ABBREVIATIONS